# Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies

> **NCT01179399** · PHASE1 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Advanced Nonhematological Malignancies

## Interventions

- **DRUG:** TAK-960

## Key facts

- **NCT ID:** NCT01179399
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2012-10
- **Final completion:** 2013-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01179399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01179399, "Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01179399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*